Arizona State University’s Erica Forzani and Pamela Marshall are answering the call for leading-edge technology solutions that benefit society. As a result of their work, they’ve been named as senior members of the National Academy of Inventors.
March 3, 2021
Inventing critical devices that monitor health, unravelling the secrets of potentially game-changing proteins, building connections with clinical partners and nurturing the future STEM workforce — that’s all in a day’s work for Arizona State University researchers Erica Forzani and Pamela Marshall.
To recognize their contributions to science and society, the National Academy of Inventors has named these researchers as senior members — two out of a class of 63 for spring 2021.
According to the NAI, this honor is given to acknowledge those who produce technologies with real societal impact, foster a spirit of innovation within their communities and educate the next generation of inventors.
“These researchers not only contribute to the community of innovation at ASU, they also embody an inventive and entrepreneurial drive to bring solutions out of the lab and into the world,” says Sally C. Morton, executive vice president of the ASU Knowledge Enterprise. “With their focus on developing technologies that make a difference in people’s lives, they reflect the goal in our university’s charter of assuming fundamental responsibility for the economic, social, cultural and overall health of the communities we serve.”
A monarch of metabolic monitoring
Chemical engineer Erica Forzani has contributed to the development of many important medical devices and technological advances during her career, particularly in the area of monitoring patients’ metabolisms.
Among the achievements that have earned her NAI senior member status are the first mobile device capable of detecting inflammatory biomarkers for asthma, the first point-of-care mobile sensor for real-time detection of carbon dioxide, the first mobile metabolic rate tracker, and a device that detects ammonia in biological fluids to diagnose signs of urea metabolism problems, liver disease and other diseases.
In total, Forzani holds 10 patents, 11 patent applications and three transferred intellectual properties and has written more than 90 peer-reviewed publications in science, engineering and medical research journals.
Forzani leads the company Breezing, which arose from sensor technology she helped to create. The company’s device enables health care professionals to obtain metabolic data used to design personalized nutritional, weight and obesity management strategies.
Co-founding the company is one of the ways she is fulfilling a goal to take her career beyond the classroom and the lab.
Forzani has also co-founded Sequitur Health Corporation with fellow Fulton Schools associate professor of chemical engineering Marylaura Lind Thomas and Mayo Clinic physician Dr. Leslie Thomas. The ASU spinoff venture focuses on medical devices for disease diagnosis with biomarker detection in body fluids. The technology is based on two ideas for which Forzani has been granted intellectual property rights.
One of her inventions has played an especially critical role over the last year. Developed in collaboration with Dr. Bhavesh Patel, a Mayo Clinic physician, it prevents dispersion of aerosols and moisture droplets in the air. Since the start of the COVID-19 pandemic, hospitals have used the device to help stop the spread of the disease and provide a safer overall environment for health care workers and patients.
Colleagues who recommended Forzani for NAI senior membership noted that her collaborations with Mayo Clinic physicians have spanned from pulmonary care, exercise physiology, intensive care and nephrology to gastroenterology, cancer therapy and genetics. She has also worked with Barrow Neurological Institute on improving care for people with dementia.
Marshall is part of a multidisciplinary team that includes Carl Wagner and Peter Jurutka, both faculty in the same school. The team focuses on modulating a protein inside cells called the rexinoid X receptor (RXR). This critical protein is a promising target for anti-cancer drugs and therapies for Alzheimer’s Disease and Parkinson’s Disease. In fact, the team’s work suggests that RXR may have a key role to perform in many different diseases.
“Together we have developed, synthesized, and tested almost 100 rexinoid compounds that we are studying for use to potentially treat cancer and neurodegenerative diseases,” Marshall says.
In addition to her game-changing research, Marshall is also paving the way for future generations of STEM researchers. In her lab, she has individually mentored over 100 undergraduate students, including many underrepresented students.
Supporting underrepresented populations in STEM and helping stimulate institutional change are a central part of Marshall’s role at ASU. She has worked with various programs, including the STEM-focused TRIO Student Support Services Program on the West campus, which supports first-generation students, low-income students and students with disabilities by providing mentoring and networking opportunities.
More recently, she became the director of an NSF-funded S-STEM Scholarship Program for low-income STEM majors, which partners with community colleges to offer professional development and award scholarships that support students throughout their higher education journeys. She is also a co-director of an NIH-funded summer program in environmental health science for underrepresented students in STEM who wish to explore careers in research. Termed the New College Environmental Health Science Scholars, this program helps connect interested students with research experiences and professional development.
Additionally, Marshall makes an effort to bring innovation into her classroom. In her upper-level course, “Fundamentals of Pharmacology,” she goes beyond teaching about drugs to focus on how the most effective drug discovery and design process is interdisciplinary and creative, helping to train the next generation of inventors.